Drug Trial Radar · NCT06239727
Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
Last checked: Nov 19, 2026Latest source record: Mar 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
593
Planned (sponsor's estimate)
Start
Mar 1, 2024
Primary completion
Feb 20, 2027
Study completion Feb 20, 2030
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
- First posted
- Feb 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.
Conditions
- Nasopharyngeal Carcinoma
Interventions
PD-1 blocking antibodyDrug
1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC. 2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
GemcitabineDrug
Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Cisplatin (80 mg/m2)Drug
Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Reduced-dose Intensity-modulated radiotherapyRadiation
1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F.
Conventional-dose Intensity-modulated radiotherapyRadiation
1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.
Cisplatin (100 mg/m2)Drug
Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
CapecitabineDrug
Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Locoregional failure-free survival (LRFFS)Time frame: 3-year
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Chongqing Cancer Hospital
Chongqing, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Recruiting
The First People's Hospital of Foshan
Foshan, Guangdong, China · Recruiting
Sun Yat-Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The Affiliated Panyu Central Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
Cancer Hospital of Shantou University Medical College
Shantou, Guangdong, China · Recruiting
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China · Recruiting
Guangdong Nongken Central Hospital
Zhanjiang, Guangdong, China · Recruiting
Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China · Recruiting
Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Recruiting
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan, China · Recruiting
Hubei Province Cancer Hosiptal
Wuhan, Hubei, China · Recruiting
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China · Recruiting
Jiangsu Provinee Hospital of Chinese Medicine
Nanjing, Jiangsu, China · Recruiting
Jiangxi Cancer Center
Nanchang, Jiangxi, China · Recruiting
The First Affiliated Hospital of Xian Jiaotong University
Xian, Shanxi, China · Recruiting
Sichuan Cancer Hospital
Chengdu, Sichuan, China · Recruiting
West China Hospital,Sichuan University
Chengdu, Sichuan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.